Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • (±)-Baclofen br Guaman Ortiz L M Croce

    2020-03-24


    Guaman Ortiz, L.M., Croce, A.L., Aredia, F., Sapienza, S., Fiorillo, G., Syeda, T.M., Buzzetti, F., Lombardi, P., Scovassi, A.I., 2015. Effect of new berberine derivatives on colon cancer cells. Acta Biochim. Biophys. Sin. 47, 824–833. Hirsch, H.A., Iliopoulos, D., Tsichlis, P.N., Struhl, K., 2009. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 69, 7507–7511. Hirsch, H.A., Iliopoulos, D., Struhl, K., 2013. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc.
    Marverti, G., Ligabue, A., Lombardi, P., Ferrari, S., Monti, M.G., Frassineti, C., Costi, M.P., 2013. Modulation of the expression of folate cycle enzymes and polyamine metabolism by berberine in cisplatin-sensitive and -resistant human ovarian cancer cells. Int. J. Oncol. 43, 1269–1280.
    Pierpaoli, E., Damiani, E., Orlando, F., Lucarini, G., Bartozzi, B., Lombardi, P., Salvatore, C., Geroni, C., Donati, A., Provinciali, M., 2015. Antiangiogenic and antitumor activities of berberine derivative NAX014 compound in a transgenic murine model of HER2/neu-positive mammary carcinoma. Carcinogenesis 36, 1169–1179. Pierpaoli, E., Fiorillo, G., Lombardi, P., Salvatore, C., Geroni, C., Piacenza, F., Provinciali, M., 2018. Antitumor activity of NAX060: a novel semisynthetic berberine
    S.M. Akula, et al. Advances in Biological Regulation xxx (xxxx) xxxx
    19  Ability of a urine gene expression classifier to reduce the number of follow-up cystoscopies in (±)-Baclofen cancer patients
    RUTH MONTALBO, JUAN J. LOZANO, LAURA IZQUIERDO, MERCEDES INGELMO-TORRES, e CARMEN BANOS, JOAN PALOU, ANTOINE G. VAN DER HEIJDEN, RAFAEL MEDINA, JOERG SCHMIDBAUER, ALEIX PRAT, MARIA J. RIBAL, ANTONIO ALCARAZ, and LOURDES MENGUAL
    BARCELONA, AND SEVILLA, SPAIN; NIJMEGEN, THE NETHERLANDS; AND VIENNA, AUSTRIA
    This study aimed to improve our previous urine gene expression classifiers focusing on the detection of non high-risk non muscle-invasive bladder cancer (NMIBC), and develop a new classifier able to decrease the frequency of cystoscopies during bladder cancer (BC) patients’ surveillance. A total of 597 urines from BC patients, controls and patients in follow-up for BC (PFBC) were included. The study has 3 phases. In the urinary biomarker discovery phase, 84 urines from BC and control patients were retrospectively included and analyzed by Ribonucleic Acid (RNA) sequencing. In the classifier development phase, a total of 132 selected genes from previous phase were evaluated by nCounter in 214 prospectively collected urines from PFBC (98 with tumor). A diagnostic classifier was generated by logistic regres-sion. Finally, in the classifier validation phase, a multicentric and international cohort of 248 urines (134 BC and 114 nonrecurrent PFBC) was used to validate classi-fier performance. A total of 521 genes were found differentially expressed between non high-risk NMIBC samples and all other groups (P < 0.05). An 8-gene diagnostic classifier with an area under curve (AUC) of 0.893 was developed. Validation of this classifier in a cohort of PFBC achieved an overall sensitivity (SN) and a negative pre-dictive value (NPV) of 96% and 97%, respectively (AUC = 0.823). Notably, this accu-racy was maintained in non high-risk NMIBC group (SN = 94%; NPV = 98%). In conclusion, this 8-gene expression classifier has high SN and NPV in a real clinical scenario. The use of this classifier can reduce the number of follow-up cystoscopies in PFBC, although assessing its final place in clinical setting is necessary. (Transla-tional Research 2019; 208:73 84) r>